Stockscreener 앱 받기
106.28
1.96%
-2.13
시간 외 거래:
106.00
-0.28
-0.26%
전일 마감가:
$108.41
열려 있는:
$109.5
하루 거래량:
642.29K
Relative Volume:
0.75
시가총액:
$11.66B
수익:
$1.64B
순이익/손실:
$121.85M
주가수익비율:
69.01
EPS:
1.54
순현금흐름:
$-480.40M
1주 성능:
-1.55%
1개월 성능:
-9.00%
6개월 성능:
-25.91%
1년 성능:
-19.66%
1일 변동 폭
$106.02
$110.00
1주일 범위
$101.15
$110.00
52주 변동 폭
$101.15
$173.25
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
106.28 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Sarepta Therapeutics (SRPT) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
Rhumbline Advisers Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
AlphaCentric Advisors LLC Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? - Insider Monkey
15 Best Fast Growth Stocks To Buy Right Now - Insider Monkey
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround - MSN
Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week LowHere's Why - MarketBeat
Van ECK Associates Corp Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - Benzinga
Sarepta Therapeutics Closes $600M in Senior Secured Revolving Credit Facility - citybiz
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Peregrine Capital Management LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 84,926 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock - MSN
SRPT Quantitative Stock Analysis - Nasdaq
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Sarepta stock touches 52-week low at $101.32 amid market challenges - Investing.com
Braun Stacey Associates Inc. Sells 2,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat
Banque Pictet & Cie SA Has $5.35 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Fiera Capital Corp Sells 9,667 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
Sarepta closes on $600M revolving credit facility - MSN
Sovran Advisors LLC Invests $3.21 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics closes on $600M credit facility - TradingPedia
Sapient Capital LLC Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
WCM Investment Management LLC Buys 12,060 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility - Marketscreener.com
Sarepta Therapeutics Closes $600 Million Revolving Credit Facility -February 14, 2025 at 09:08 am EST - Marketscreener.com
Major Banks Back Sarepta With $600M Credit Facility: Financial Power Move Revealed - StockTitan
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Sarepta Q4 Earnings Preview: Rare Disease Leader's Full-Year Performance Revealed - StockTitan
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLC - MarketBeat
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results - Business Wire
Deutsche Bank sets Sarepta stock target at $136, cites risks - MSN
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Hold Rating, $136 Price Target - Marketscreener.com
Tobam Has $3.52 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug - StockTitan
Arrowhead Closes Licensing, Collaboration Agreement With Sarepta -February 10, 2025 at 09:39 am EST - Marketscreener.com
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - BioSpace
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):